Back to top

Image: Bigstock

Horizon (HZNP) Q2 Earnings Down Y/Y, Tepezza Drives Sales

Read MoreHide Full Article

Horizon Therapeutics plc  reported second-quarter 2020 adjusted earnings of 40 cents per share, which lagged the year-ago quarterly earnings of 49 cents per share. The Zacks Consensus Estimate stood at 40 cents.

Quarterly sales of $462.8 million were up 44% year over year. The top line also beat the Zacks Consensus Estimate of $365 million.Sales were driven by the strong launch of Tepezza, despite a challenging COVID-19 environment.

Horizon Therapeutics’ share price increased 23.6% following the earnings release as it raised its guidance for 2020. In fact, theshare price has skyrocketed 103.9% year to date compared with the industry’s increase of 5.7%.


Quarter in Detail

The company reports financial results under two separate segments —Orphan and Rheumatology, and Inflammation (previously known as the primary care segment). Notably, first-quarter 2020 onward, the Orphan and Rheumatology segment was renamed the Orphan segment.

Sales inthe Orphan segment were $379.3 million, up 87% from the prior-year figure, driven by continued growth of drugs like Tepezza and Ravicti.

Krystexxa sales declined 6% year over year to $75.2 million,reflecting the impact of COVID-19. Tepezza generated net sales worth $165.9 million in the second quarter which exceeded the company’s expectations up from  sales $23.5 million in the sequentially prior quarter. In January 2020, the FDA approved Tepezza for the treatment of thyroid eye disease (TED), well ahead of the set action date of Mar 8, 2020.

Ravicti sales were $65.6 milllion in the quarter, up 30% year over year.

Second-quarter 2020 net sales inthe Inflammation segment were $83.5 million, down 29% year over year, reflecting the impacts of COVID-19.

Adjusted R&D expenses were $28.2 million, up from $21.9 million in the year-ago quarter. Adjusted SG&A expenses were $191.4 million, up from $145.4 million in the year-ago quarter.

2020 Guidance

Per the company, owing to the strong uptake of Tepezza and its substantially higher revenues that more than offset the expected adversity from the COVID-19 pandemic, Horizon Therapeutics significantly raised its full-year sales expectations fromTepezza and correspondingly the net sales guidance.

The company now expects 2020 net sales of $1.85-$1.90 billion, an increase from the previous guidance range of $1.40-$1.45 billion. The company now expects Tepezza’s2020 net sales to bemorethan $650 million compared with the previous guidance of greater than $200 million. 

Other Pipeline Updates

In April, Horizon Therapeutics acquired the privately-held, biopharma company, Curzion Pharmaceuticals, Inc., and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, CZN001 (renamed HZN-825), for the treatment of diffuse cutaneous systemic sclerosis (dcSSc).

 

Zacks Rank & Other Stocks to Consider

Horizon Therapeutics currently carries a Zacks Rank #1 (Strong Buy). Some other similar-ranked stocks in the healthcare sector include AC IMMUNE SA. (ACIU - Free Report) , Emergent Biosolutions Inc. (EBS - Free Report) and Alimera Sceinces Inc. (ALIM - Free Report) . You can see the complete list of today’s Zacks #1 Rank stocks here.

AC IMMUNE’s loss per share estimates have narrowed from 92 cents to 90 cents for 2020 over the past 60 days.

Emergent’s earnings estimates have increasedfrom $2.85 to $5.60 for 2020 and from $3.35 to $6.67 for 2021 over the past 60 days.

Alimera’s loss per share estimates have narrowed from $2.33 to $1.31 for 2020 and from 63 cents to 52 cents for 2021 over the past 60 days.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.

Click here for the 6 trades >>


Unique Zacks Analysis of Your Chosen Ticker


Pick one free report - opportunity may be withdrawn at any time


Alimera Sciences, Inc. (ALIM) - $25 value - yours FREE >>

Emergent Biosolutions Inc. (EBS) - $25 value - yours FREE >>

AC Immune (ACIU) - $25 value - yours FREE >>

Published in